Swiss specialty chmicals group Lonza has granted US biotechnology major Genentech a non-exclusive, worldwide license to its GS Gene Expression System.
The research evaluation agreement covers use of the GS System for R&D and includes options for a multi-product license for commercial purposes, and further options to obtain licenses for the use of Lonza's proprietary Protein-Free Media System for both purposes. The deal includes license fees and milestone payments; financial terms were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze